Sequential bilateral transplantation in Parkinson's disease: effects of the second graft
(1999) In Brain 122(6). p.1121-1132- Abstract
- Five parkinsonian patients who had received implants of human embryonic mesencephalic tissue unilaterally in the striatum 10-56 months earlier were grafted with tissue from four to eight donors into the putamen (four patients) or the putamen plus the caudate nucleus (one patient) on the other side, and were followed for 18-24 months. After 12-18 months, PET showed a mean 85% increase in 6-L-[18F]fluorodopa uptake in the putamen with the second graft, whereas there was no significant further change in the previously transplanted putamen. Two patients exhibited marked additional improvements after their second graft: 'on-off' fluctuations virtually disappeared, movement speed increased, and L-dopa could be withdrawn in one patient and... (More)
- Five parkinsonian patients who had received implants of human embryonic mesencephalic tissue unilaterally in the striatum 10-56 months earlier were grafted with tissue from four to eight donors into the putamen (four patients) or the putamen plus the caudate nucleus (one patient) on the other side, and were followed for 18-24 months. After 12-18 months, PET showed a mean 85% increase in 6-L-[18F]fluorodopa uptake in the putamen with the second graft, whereas there was no significant further change in the previously transplanted putamen. Two patients exhibited marked additional improvements after their second graft: 'on-off' fluctuations virtually disappeared, movement speed increased, and L-dopa could be withdrawn in one patient and reduced by 70% in the other. The improvement in one patient was moderate. Two patients with atypical features, who responded poorly to the first graft, worsened following the second transplantation. These findings indicate that sequential transplantation in patients does not compromise the survival and function of either the first or the second graft. Moreover, putamen grafts that restore fluorodopa uptake to normal levels can give improvements of major therapeutic value. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1114613
- author
- organization
- publishing date
- 1999
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- neural grafting, Parkinson’s disease, dopamine, striatum, positron emission tomography
- in
- Brain
- volume
- 122
- issue
- 6
- pages
- 1121 - 1132
- publisher
- Oxford University Press
- external identifiers
-
- pmid:10356064
- scopus:0032692348
- ISSN
- 1460-2156
- DOI
- 10.1093/brain/122.6.1121
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Neurobiology (013212024), Neurology, Lund (013027000), Neuronal Survival (013212041), Neurosurgery (013026000), Caring Sciences (Closed 2012) (016514020)
- id
- 34c0957e-8abe-4244-9645-8dfd6bd43a4e (old id 1114613)
- date added to LUP
- 2016-04-01 11:44:38
- date last changed
- 2022-12-10 17:38:14
@article{34c0957e-8abe-4244-9645-8dfd6bd43a4e, abstract = {{Five parkinsonian patients who had received implants of human embryonic mesencephalic tissue unilaterally in the striatum 10-56 months earlier were grafted with tissue from four to eight donors into the putamen (four patients) or the putamen plus the caudate nucleus (one patient) on the other side, and were followed for 18-24 months. After 12-18 months, PET showed a mean 85% increase in 6-L-[18F]fluorodopa uptake in the putamen with the second graft, whereas there was no significant further change in the previously transplanted putamen. Two patients exhibited marked additional improvements after their second graft: 'on-off' fluctuations virtually disappeared, movement speed increased, and L-dopa could be withdrawn in one patient and reduced by 70% in the other. The improvement in one patient was moderate. Two patients with atypical features, who responded poorly to the first graft, worsened following the second transplantation. These findings indicate that sequential transplantation in patients does not compromise the survival and function of either the first or the second graft. Moreover, putamen grafts that restore fluorodopa uptake to normal levels can give improvements of major therapeutic value.}}, author = {{Hagell, Peter and Schrag, A and Piccini, P and Jahanshahi, M and Brown, R and Rehncrona, Stig and Widner, Håkan and Brundin, Patrik and Rothwell, J C and Odin, Per and Wenning, G K and Morrish, P and Gustavii, B and Björklund, Anders and Brooks, D J and Marsden, C D and Quinn, N P and Lindvall, Olle}}, issn = {{1460-2156}}, keywords = {{neural grafting; Parkinson’s disease; dopamine; striatum; positron emission tomography}}, language = {{eng}}, number = {{6}}, pages = {{1121--1132}}, publisher = {{Oxford University Press}}, series = {{Brain}}, title = {{Sequential bilateral transplantation in Parkinson's disease: effects of the second graft}}, url = {{http://dx.doi.org/10.1093/brain/122.6.1121}}, doi = {{10.1093/brain/122.6.1121}}, volume = {{122}}, year = {{1999}}, }